From the 3B's Research Group (Dr. Costa-Almeida, Dr. Babo, Dr. Reis, and Dr. Gomes), I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, the ICVS/3B's-PT Government Associate Laboratory (Dr. Costa-Almeida, Dr. Babo, Dr. Reis, and Dr. Gomes), Braga/Guimarães, and the The Discoveries Centre for Regenerative and Precision Medicine (Dr. Reis and Dr. Gomes), Headquarters at University of Minho, Guimarães, Portugal.
J Am Acad Orthop Surg. 2020 Mar 1;28(5):e202-e205. doi: 10.5435/JAAOS-D-18-00638.
Tendon injuries constitute a significant healthcare problem with variable clinical outcomes. The complex interplay of tissue homeostasis, degeneration, repair, and regeneration makes the development of successful delivery therapeutic strategies challenging. Platelet-rich hemoderivatives, a source of supra-physiologic concentrations of human therapeutic factors, are a promising application to treat tendon injuries from the perspective of tendon tissue engineering, although the outcomes remain controversial.
肌腱损伤是一个严重的医疗保健问题，其临床结果具有变异性。组织内稳态、退变、修复和再生的复杂相互作用使得成功开发输送治疗策略具有挑战性。富含血小板的血液衍生物是一种来源，它提供了超生理浓度的人类治疗因子，从肌腱组织工程的角度来看，这是一种很有前途的治疗肌腱损伤的应用，尽管其结果仍存在争议。
